Loading, Please wait ...

Please contact us if you would like to upgrade your account to include access to financial models

Please contact us if you would like to upgrade your account to include short term strategies for this stock.

AZN.N

ISIN: US0463531089
SEDOL: 2989044

Rating:

BUY

Target Price:

49.09 USD

Investment Horizon:

6 to 12 months
30th Apr 2009 View Report   Download

1Q 09 News Alert

AstraZeneca PLC (AstraZeneca) reported flat sales growth in 1Q 09. Although sales was marginally below our estimate, operating and net performance exceeded our expectations in 1Q 09. Considering the better-than-expected operating and net performance by AstraZeneca, we may revise our estimates upwards. Hence, we maintain our current BUY rating for the ADR. We will reassess our target price and rating in our 1Q 09…

6th Mar 2009 View Report   Download

Company News Alert

AstraZeneca PLC’s (AstraZeneca) ADR price has experienced a significant decline of 20.6% since our 4Q 08 and FY 2008 update report dated, 30 January 2009, due to negative investor sentiments associated with concerns over weakening global economic growth, coupled with turbulence in global financial markets. However, we maintain our positive outlook for the company as we continue to expect strong growth in revenues from its…

30th Jan 2009 View Report   Download

4Q 08 & FY 2008 Update Report

CLICK VIEW REPORT TO READ FREE REPORT

In 4Q 08, Teva Pharmaceutical Industries Ltd. (Teva) made an unanticipated at-risk generic launch of Pulmicort Repsules (which contributed 5% of AstraZeneca’s net sales in FY 2008). Following a settlement, Teva has pulled this launch but will market a generic version from FY 2010, denting AstraZeneca’s sales performance over the medium-to-long term. However, this should be more than offset by strong sales of the upcoming…

20th Nov 2008 View Report   Download

Company News Alert

CLICK VIEW REPORT TO READ FREE REPORT

AstraZeneca PLC’s (AstraZeneca) ADR price has experienced a significant decline of 12.2% in a single trading session, primarily due to earlier than anticipated launch of generic version of Pulmicort Respules (PR) and disappointing results from the Phase III clinical trials for Zactima, used for the treatment of lung cancer. However, we maintain our positive outlook for the company as we continue to expect strong growth in revenues…

18th Nov 2008 View Report   Download

3Q 08 Update Report

CLICK VIEW REPORT TO READ FREE REPORT

AstraZeneca PLC (AstraZeneca) reported improved revenue performance, in line with our expectations for 3Q 08, primarily driven by its key products; Seroquel, Crestor and Symbicort (collectively comprising 33% of 3Q 08 total revenues). Going forward, we remain optimistic for the recent US Food and Drug Administration (FDA) approvals for Seroquel and greater penetration of Crestor in the US and European markets. Moreover…